DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Completed

Conditions: Chronic Pancreatitis

Interventions: Drug: CREON

First Posted Date: 2021-07-02

Last Posted Date: 2024-03-28

Lead Sponsor: AbbVie

Target Recruit Count: 63

Registration Number: NCT04949828

Locations: 🇺🇸
John Hopkins University /ID# 227061, Baltimore, Maryland, United States
🇺🇸
Baylor College of Medicine - Baylor Medical Center /ID# 227067, Houston, Texas, United States
🇺🇸
NYU Langone Health /ID# 230818, New York, New York, United States

and more 3 locations

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Phase 2

Completed

Conditions: Non-Segmental Vitiligo

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2021-06-16

Last Posted Date: 2024-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 185

Registration Number: NCT04927975

Locations: 🇺🇸
Duplicate_UMass Chan Medical School /ID# 228066, Worcester, Massachusetts, United States
🇺🇸
Duplicate_Michigan Center for Research Company /ID# 228054, Clarkston, Michigan, United States
🇺🇸
Oregon Medical Research Center /ID# 228073, Portland, Oregon, United States

and more 32 locations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Telisotuzumab Vedotin
Drug: Docetaxel

First Posted Date: 2021-06-16

Last Posted Date: 2025-05-23

Lead Sponsor: AbbVie

Target Recruit Count: 698

Registration Number: NCT04928846

Locations: 🇺🇸
City Of Hope - Seacliff /ID# 263143, Huntington Beach, California, United States
🇺🇸
University of Alabama at Birmingham - Main /ID# 247074, Birmingham, Alabama, United States
🇺🇸
Ironwood Cancer & Res Ctr /ID# 262446, Chandler, Arizona, United States

and more 294 locations

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Phase 2

Terminated

Conditions: Onchocerciasis

Interventions: Drug: ABBV-4083
Drug: Placebo for ABBV-4083
Drug: Albendazole
Drug: Placebo for Albendazole

First Posted Date: 2021-06-04

Last Posted Date: 2023-09-21

Lead Sponsor: AbbVie

Target Recruit Count: 153

Registration Number: NCT04913610

Locations: 🇨🇩
Hôpital Général de Référence de Kimpese, Kimpese, Kongo Central, Congo, The Democratic Republic of the
🇨🇩
Hôpital Général de Référence de Masi-Manimba, Masi-Manimba, Kwilu, Congo, The Democratic Republic of the

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

Interventions: Drug: Lemzoparlimab
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2021-06-03

Last Posted Date: 2024-02-26

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT04912063

Locations: 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 227275, Jerusalem, Yerushalayim, Israel
🇦🇺
Austin Health /ID# 227717, Heidelberg, Victoria, Australia
🇮🇱
Rabin Medical Center /ID# 227738, Petakh Tikva, Israel

and more 26 locations

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab
Drug: Apremilast

First Posted Date: 2021-06-01

Last Posted Date: 2024-04-30

Lead Sponsor: AbbVie

Target Recruit Count: 352

Registration Number: NCT04908475

Locations: 🇺🇸
Epiphany Dermatology of Kansas LLC /ID# 229221, Overland Park, Kansas, United States
🇺🇸
Center for Clinical Studies - Houston (Binz) /ID# 229272, Houston, Texas, United States
🇺🇸
UC Davis Health /ID# 229133, Sacramento, California, United States

and more 51 locations

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir (GLE/PIB)

First Posted Date: 2021-05-26

Last Posted Date: 2025-04-06

Lead Sponsor: AbbVie

Target Recruit Count: 286

Registration Number: NCT04903626

Locations: 🇺🇸
Duplicate_University Of Cincinnati Medical Center /ID# 226922, Cincinnati, Ohio, United States
🇮🇹
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 227080, Bologna, Emilia-Romagna, Italy
🇺🇸
Arizona Health Research /ID# 233558, Chandler, Arizona, United States

and more 67 locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Venetoclax
Drug: Obinutuzumab

First Posted Date: 2021-05-20

Last Posted Date: 2025-04-25

Lead Sponsor: AbbVie

Target Recruit Count: 75

Registration Number: NCT04895436

Locations: 🇧🇬
UMHAT Sveti Georgi EAD /ID# 272321, Plovdiv, Bulgaria
🇦🇹
Hanusch Krankenhaus /ID# 230010, Wien, Austria
🇩🇪
OncoResearch Lerchenfeld GmbH /ID# 230191, Hamburg, Germany

and more 51 locations

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Lemzoparlimab
Drug: Dexamethasone
Biological: Daratumumab
Drug: Carfilzomib
Drug: Pomalidomide

First Posted Date: 2021-05-20

Last Posted Date: 2023-03-06

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT04895410

Locations: 🇺🇸
Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States
🇺🇸
Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States
🇺🇸
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States

and more 29 locations

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Phase 2

Terminated

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: ABBV-154
Drug: Placebo

First Posted Date: 2021-05-17

Last Posted Date: 2024-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 473

Registration Number: NCT04888585

Locations: 🇺🇸
Purushotham & Akther Kotha MD, Inc /ID# 228120, La Mesa, California, United States
🇺🇸
International Medical Research /ID# 228069, Daytona Beach, Florida, United States
🇺🇸
Neoclinical Research /ID# 228753, Hialeah, Florida, United States

and more 217 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy